The discovery in the late 1980s that over 20% of breast cancer cells overexpressed HER2-RTKs on their surfaces, ushered in a new approach to cancer treatment directed at targeting the expression of tumor biomarkers and disrupting the activity of gene products. The gene discussed is ERBB2; the disease is cancer.